NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 1,685.00
+85.00 (5.31%)
Last updated: Nov 17, 2025, 9:46 AM KST
NGeneBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | -0 | -0 | 0 | - | - |
| 9,985 | 5,691 | 4,351 | 11,018 | 7,163 | |
Revenue Growth (YoY) | 61.66% | 30.80% | -60.51% | 53.81% | - |
Cost of Revenue | 8,041 | 3,606 | 4,505 | 6,889 | 4,773 |
Gross Profit | 1,943 | 2,085 | -153.65 | 4,128 | 2,390 |
Selling, General & Admin | 10,535 | 12,677 | 7,834 | 7,389 | 6,011 |
Research & Development | 1,850 | 2,805 | 4,505 | 4,584 | 4,456 |
Amortization of Goodwill & Intangibles | 378.38 | 329.01 | 185.36 | 178 | 147.24 |
Other Operating Expenses | 651.87 | 603.4 | 58.85 | 69.25 | 148.6 |
Operating Expenses | 15,268 | 18,160 | 13,271 | 12,728 | 11,122 |
Operating Income | -13,324 | -16,075 | -13,425 | -8,599 | -8,732 |
Interest Expense | -1,272 | -1,804 | -1,781 | -665.44 | -155.25 |
Interest & Investment Income | 68.85 | 224.34 | 991.59 | 852.58 | 261.76 |
Earnings From Equity Investments | - | - | - | - | 199.05 |
Currency Exchange Gain (Loss) | 138.35 | 223.79 | 23.95 | 84.28 | 0.71 |
Other Non Operating Income (Expenses) | 1,936 | 3,858 | 1,659 | -1,332 | 28.42 |
EBT Excluding Unusual Items | -12,452 | -13,573 | -12,531 | -9,660 | -8,397 |
Gain (Loss) on Sale of Investments | -433.5 | -503.72 | -526.16 | -144.52 | 1.77 |
Gain (Loss) on Sale of Assets | -32.38 | -14.8 | -20.85 | -0.99 | -11.15 |
Asset Writedown | -60.38 | -34.04 | -97.62 | -34.1 | -24.56 |
Other Unusual Items | -1,154 | -145.5 | - | - | - |
Pretax Income | -14,133 | -14,271 | -13,175 | -9,839 | -8,431 |
Income Tax Expense | -328.88 | -328.88 | -315.69 | - | - |
Earnings From Continuing Operations | -13,804 | -13,942 | -12,860 | -9,839 | -8,431 |
Minority Interest in Earnings | 1,363 | 1,315 | 90.92 | 53.96 | - |
Net Income | -12,956 | -12,628 | -12,769 | -9,785 | -8,431 |
Net Income to Common | -12,956 | -12,628 | -12,769 | -9,785 | -8,431 |
Shares Outstanding (Basic) | 19 | 14 | 13 | 12 | 12 |
Shares Outstanding (Diluted) | 19 | 17 | 13 | 12 | 12 |
Shares Change (YoY) | 50.74% | 31.30% | 1.66% | 0.89% | - |
EPS (Basic) | -666.82 | -890.26 | -1006.63 | -784.21 | -681.70 |
EPS (Diluted) | -824.02 | -941.56 | -1007.00 | -784.21 | -682.00 |
Free Cash Flow | -8,861 | -12,566 | -9,553 | -8,849 | -10,546 |
Free Cash Flow Per Share | -456.05 | -754.48 | -753.13 | -709.15 | -852.68 |
Gross Margin | 19.46% | 36.63% | -3.53% | 37.47% | 33.36% |
Operating Margin | -133.45% | -282.47% | -308.56% | -78.05% | -121.90% |
Profit Margin | -129.76% | -221.89% | -293.48% | -88.82% | -117.70% |
Free Cash Flow Margin | -88.74% | -220.81% | -219.57% | -80.32% | -147.22% |
EBITDA | -10,530 | -13,139 | -12,081 | -7,325 | -7,702 |
EBITDA Margin | -105.46% | -230.88% | -277.67% | -66.49% | -107.52% |
D&A For EBITDA | 2,794 | 2,936 | 1,344 | 1,274 | 1,030 |
EBIT | -13,324 | -16,075 | -13,425 | -8,599 | -8,732 |
EBIT Margin | -133.45% | -282.47% | - | -78.05% | -121.90% |
Advertising Expenses | - | 656.19 | 348.42 | 336.73 | 287.33 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.